AMID THE FLOOD OF BAD NEWS about the coronavirus, in April there was a buoy: A major clinical trial showed that an antiviral medication called remdesivir shortened the length of time that patients are sick with covid19, from a median of 15 days down to 11. The FDA had already rushed to approve research on the compound—an underperforming Ebola drug— and when the trial results came in, the agency quickly authorized it for emergency use. There are caveats: It’s not clear whether the drug reduces a patient’s risk of dying from the disease, and a small Chinese study showed no benefit. Still, doctors are hopeful that remdesivir will help reduce strain on hospitals and buy time for researchers to develop other treatments and a vaccine. In the meantime, remdesivir’s manufacturer, the pharmaceutical company Gilead, could help millions of people and make billions of dollars.
That’s how pharma companies say it’s supposed to work: Profit spurs innovation. But it doesn’t always happen that way. Sometimes the opposite is true. Because of the perverse incentive structure of medical patents, Gilead has made enormous sums of money by delaying the development of its own HIV medication for the people who need it.
In the late 1990s, Gilead made a breakthrough in HIV treatment when it found that the molecule tenofovir disoproxil fumarate, or TDF, could stop HIV from replicating. In 2005, Gilead’s TDF-based drug Truvada made $570 million in sales, and up to $2.7 billion in 2010. TDF’s side effects—decreased kidney function and bone mass—were milder than those of rival drugs, and seemed a small price for turning a death sentence into a chronic illness.
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
WHEN IN DROUGHT
This obscure yet adaptable grain could be a healthy staple for a warming planet.
GLOBAL WARNING
Why Project 2025 is an environmental catastrophe in the making
BAD HABITS
A spate of recent horror movies recycle tired tropes about nuns-and reveal society's ongoing discomfort with independent women.
Taking the Fifth For a glimpse of the Supreme Court after a second Trump term, look at the radical circuit court that's already driving America to the right.
Imagine obamacare is dead and millions of Americans have lost health coverage.
THE ARCHITECT
TRUMP WANTS TO BE KING. RUSS VOUGHT HAS A PLAN TO MAKE IT HAPPEN.
Losing Faith
As an evangelical leader, I enticed lawmakers and federal judges to adopt a conservative Christian agenda. Donald Trump’s rise proved how wrong I was.
GOD'S COUNTRY
These Christian nationalists have a plan to take over Americafrom small towns to the highest court in the land.
IN THE NAME OF THE MOTHER
How Shyamala Gopalan Harris raised a presidential contender
KILL THE MESSENGER
The anti-disinformation field is retreating under attack.
TRUMPNESIA
To get a second chance, Trump needs voters to forget his disastrous presidency.